The Egyptian Company for Blood Transfusion Services   Report issue

Foundation Phase 3
Founded: Cairo Egypt (1938)

Organization Overview

First Clinical Trial
2008
NCT00755950
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

lactose (1 trial)

silymarin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Hepatitis C (Phase 3)

Hepatitis E (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2